Express News | Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target
Baird Initiates Apellis Pharmaceuticals(APLS.US) With Buy Rating, Announces Target Price $100
Apellis Pharmaceuticals Strengthened Market Position and Buy Rating Following Competitor's Clinical Failure
Stifel Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $84
Apellis Pharmaceuticals (APLS) Receives a Buy From Stifel Nicolaus
Citi Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $60
EZ_money OP : this is worth way more than the price